Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993576 | 0.72 | ALDH1A1 (0.43) | KCNH2 | |
| SCHEMBL14498365 | 0.72 | AKR1C3 (0.38) | AKR1C3 | |
| SCHEMBL15225979 | 0.68 | TSHR (0.46) | CNR1CNR2PIK3CAAKT1 | |
| SCHEMBL21145793 | 0.64 | KCNH2 (0.33) | KCNH2PIK3CAPIK3R1 | |
| SCHEMBL24477714 | 0.64 | KDM4E (0.41) | PIK3CAAKT1MTOR | |
| Bicarbonate SCHEMBL15225846 | 0.64 | TSHR (0.45) | — | |
| SCHEMBL2325561 | 0.63 | CA1 (0.40) | AKR1C3 | |
| SCHEMBL18286841 | 0.62 | AKR1C3 (0.33) | AKR1C3 | |
| SCHEMBL3352759 | 0.62 | INPP5A (0.47) | KCNH2CNR1CNR2PIK3CAAKT1 | |
| SCHEMBL4742018 | 0.62 | AKT1 (0.33) | KCNH2PIK3CAAKT1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | KCNH2 1893/4885CNR1 2338/4885CNR2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.